ReGen talks Colostrinin and cognition to natural health practitioners

By staff reporter

- Last updated on GMT

Related tags: Clinical trial, Medicine, Health care

ReGen and Metagenics are preparing for the launch of Colostrinin
with the presentation of data on the nutraceutical's potential for
cognitive function before a group that could be instrumental in its
success - natural health practitioners.

A review of research conducted to date was presented by ReGen's chief scientific officer Dr Marian Kruzel at the International Congress on Natural Medicine. The event is a canny pre-marketing strategy for the companies, since practitioners are often a first port of call for consumers looking for ways of improving or maintaining health through dietary supplements. Colostrinin is a trademarked complex derived from ovine and bovine colostrum (the first milk produced by a mammal after giving birth). In addition to launching Colostirin itself as a nutraceutical, the company is also developing a pharmaceutical preparation based on the peptides within it, for the treatment of Alheimer's disease. In July last year, the UK-company signed a license agreement with Metagenetics for the launch of a nutraceutcal aimed at early stage cognitive decline. It is expected that Metagencis will launch Colostrinin in the United States in Q4 2007. The congress was sponsored by Metagenics via its Australian subsidiary, Health World. A similar approach was taken by Canadian firm Advitech for its Dermylex supplement. In this case, Advitech delayed the launch of its product so as to gather additional data on its nutraceutical's potential for mild to moderate psoriasis that would help encourage dermatologists to recommend it to patients. Dr Kruzel called the audience "extraordinary… it includes physicians, health care professionals and many other disciplines concerned about wellbeing in rapidly aging societies."​ Her presentation comprised a round up of pre-clinical and human clinical data on Colostrin's role age-related cognitive decline. One aspect was the reduced production of intracellular reactive oxygen species (ROS), which increase with old age and are associated with tissue and metabolic damage. The company has also looked into the prevention of the aggregation of beta-amyloid, the protein associated with Alzheimer's disease, and its neurotoxicity. Clinical trials involving 150 human subjects with mild to moderate Alzheimer's disease have shown it to have beneficial effects on cognitive and functional performance. ReGen has also conducted animal studies to establish that Colostrinin is well-tolerated at daily doses up to 100 times that recommended for humans, over a prolonged period. Moreover, data has indicated that the nutraceutical given in the drinking water could increase the lifespan of mice prone to premature ageing by around 30 per cent. The full methodologies and results of the studies have not been seen by

Related topics: Dairy-based ingredients

Related news

Related products

show more

Consumers are ditching diets for intuitive eating.

Consumers are ditching diets for intuitive eating.

Fonterra | 02-Aug-2022 | Technical / White Paper

Interest in intuitive eating is reportedly gaining as much traction with consumers as the ketogenic diet. However, without similarly strict macronutrient...

Fonterra Keeps Your Ingredients Ahead of the Curve

Fonterra Keeps Your Ingredients Ahead of the Curve

Fonterra | 26-Jul-2022 | Technical / White Paper

With health and environmental concerns in mind, consumers’ commitment to purchasing organic products continues to grow. Whether your brand is starting...

¡Por qué WB47 podría ser su próximo acierto!

¡Por qué WB47 podría ser su próximo acierto!

Sidel Group | 19-May-2022 | Product Presentation

Con una mayor flexibilidad a nivel de empaque primario y secundario, la plataforma de empaque mejorada WB47 responde a las expectativas de diversas categorías...

Related suppliers

Follow us


View more